G. John Mohr

AtheroGenics is a pharmaceutical company focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, such as atherosclerosis, asthma and arthritis.

Immune Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Its lead product, Bertilimumab, is a human monoclonal antibody that binds eotaxin-1, a chemokine that attracts eosinophils to the site of inflammation. Bertilimumab has shown promising clinical activity in bullous pemphigoid and has been studied in other conditions including allergic rhinitis and ulcerative colitis, and may have application in other diseases, including atopic dermatitis, asthma, and other diseases. It is also developing NanoCyclo, a topical nano-encapsulated formulation of cyclosporine, for the treatment of atopic dermatitis (AD) and psoriasis. The company was founded by Daniel Gedeon Teper on March 9, 1993 and is headquartered in Englewood Cliffs, NJ.

Metabolic Testing Services Corp. provides medical diagnostics services. Its product MET-test represents the culmination in the understanding of cardiopulmonary diseases and information technology. The company was founded by William S. Woulfin, Sundeep Chaudhry and Rajesh D. Patel in 2003 and is headquartered in Atlanta, GA.

Accolade Pharma LLC is a pharmaceutical company that specializes in developing topical formulations and devices for the active ingredient of Accolate® (zafirlukast) to treat allergic inflammation. The private company is based in Wilmington, DE. Leukotriene antagonists modify allergic responses by blocking leukotrienes, which prevents or decreases symptoms of acute inflammation such as wheezing, sneezing, itching, redness, and swelling. The company was founded in 2012 by G. John Mohr, who has been the CEO since 2012.